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Oa b s t r a c t
Direct oral anticoagulants (DOACs) offer clinical advantages over warfarin, such as minimal medication
and food interactions and ﬁxed dosing without the need for routine monitoring of coagulation status. As
with all anticoagulants, bleeding, either spontaneous or provoked, is the most common complication.
The long-term use of these drugs is increasing, and there is a crucial need for emergency medicine
service professionals to understand the optimal management of associated bleeding. This review aims to
describe the indications and pharmacokinetics of available DOACs; to discuss the risk of bleeding; to
provide a treatment algorithm to manage DOAC-associated emergency bleeding; and to discuss future
directions in bleeding management, including the role of speciﬁc reversal agents, such as the recently
approved idarucizumab for reversal of the direct thrombin inhibitor dabigatran. Because air medical
personnel are increasingly likely to encounter patients receiving DOACs, it is important that they have an
understanding of how to manage patients with emergent bleeding.
Copyright © 2016 by Air Medical Journal Associates Open access under CC BY-NC-ND license.Oral anticoagulants are available for the prophylaxis and treat-
ment of thromboembolic disease, including the acute treatment
and secondary prophylaxis for venous thromboembolisms (VTEs)
and the risk reduction of stroke and systemic embolism in patients
with nonvalvular atrial ﬁbrillation (NVAF). They include the well-
established vitamin K antagonist (VKA), warfarin, and newer
agents such as direct thrombin inhibitor, dabigatran etexilate, and
the direct factor Xa inhibitors rivaroxaban, apixaban, and edox-
aban.1-4 These newer classes of drugs are known as direct oral
anticoagulants (DOACs) because their mechanisms of action
involve direct inhibition of speciﬁc serine proteases in the coagu-
lation cascade, whereas VKAs indirectly inhibit several steps in the
cascade. DOACs offer clinical advantages over warfarin.5,6 These
include predictable pharmacokinetic and pharmacodynamic ef-
fects, minimal medication and food interactions, and ﬁxed dosing
without the need for routine laboratory monitoring of coagulation
status. DOACs provide antithrombotic efﬁcacy comparable with
dose-adjusted warfarin for most indications tested; in phase III
randomized clinical trials in patients with NVAF, treatment with
DOACs was as effective as or better than warfarin in reducing the
risk for stroke.7-10 Similarly, phase III trials with DOACs in patients
with VTE showed noninferiority to warfarin for the recurrence ofD, Department of Emergency
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pen access under CC BY-NC-ND licensVTE or related death.11-14 DOACs have also been associated with a
lower risk for devastating intracranial hemorrhage (ICH) than
adjusted-dose warfarin in patients with NVAF.5 However, as with
all anticoagulants, bleeding, either spontaneous or provoked, is the
most common complication.15
The long-term use of oral anticoagulants (warfarin and DOACs)
is widespread and increasing. The most recently published data
suggest that there are > 30 million prescriptions for warfarin
annually in the United States.16 Since their introduction, DOACs
have been steadily taken up by physicians and patientsdeither
newly diagnosed or long-time warfarin users.17 Dabigatran etex-
ilate was the ﬁrst DOAC approved in the United States in October
2010, and by late 2011, it accounted for nearly 17% of oral antico-
agulant prescriptions in patients with atrial ﬁbrillation in a national
database.17 These data suggest that air medical personnel are
increasingly likely to encounter a signiﬁcant fraction of patients
taking oral anticoagulants, including DOACs.18 This is likely to apply
to both trauma and nontrauma patients. For example, signiﬁcant
increases in the portion of patients on chronic warfarin were
observed in a retrospective cohort analysis of > 1.2 million patients
admitted to 402 trauma centers, with the proportion increasing
from 2.3% in 2002 to 4.0% in 2006 (P < .001). This increase was
especially apparent in patients > 65 years of age (7.3%-12.8%,
P < .001).19 National adverse event (AE) data between 2007 and
2009 also found that warfarin (alone or in combination) was
implicated in one third of emergency hospitalizations for drug-
related AEs in older adults.20e.
Table 1
Indications for Available DOACs1-4
Dabigatran Etexilate Edoxaban Rivaroxaban Apixaban
Approved indication
Reduce the risk of stroke and systemic embolism in patients with NVAF ✓ ✓ ✓ ✓
Treatment of DVT and PE ✓ ✓ ✓ ✓
Reduce the risk of recurrence of DVT and PE ✓ ✓ ✓
Prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ✓ (hip only) ✓ ✓
AF ¼ atrial ﬁbrillation; DOAC ¼ direct oral anticoagulant; DVT ¼ deep vein thrombosis; NVAF ¼ nonvalvular atrial ﬁbrillation; PE ¼ pulmonary embolism.
R.L. Summers, S.A. Sterling / Air Medical Journal 35 (2016) 148e155 149Therefore, it is crucial that emergency medicine service (EMS)
professionals have a clear understanding of DOACs and the optimal
management of associated bleeding. Warfarin has been the stan-
dard of care in oral anticoagulation for many years, and its bleeding
risks are well-known. Supportive measures for a hemorrhaging
patient include intravenous (IV) ﬂuids to maintain volume, packed
red blood cells, and fresh frozen plasma. Although no reversal agent
for warfarin is available, vitamin K and prothrombin complex
concentrates (PCCs, including 4-factor PCC21) may be administered
to restore coagulation. However, PCCs may increase the risk for
prothrombotic events.21 For patients receiving DOAC therapy, there
have been concerns among physicians with regard to the man-
agement of serious bleeds, as highlighted by published case reports
in the literature.22-26
This review is for air medical personnel and aims to describe
available DOACs, including their indications and pharmacokinetics;
to discuss the risk of bleeding associated with different DOACs; to
provide a treatment algorithm to manage DOAC-associated emer-
gency bleeding; and to discuss future directions in the emergency
management of DOAC-associated bleeding, including the potential
role of DOAC-speciﬁc reversal agents.
General Overview of Oral Anticoagulants
Indications for Oral Anticoagulants
The direct thrombin inhibitor dabigatran and the factor Xa in-
hibitors apixaban, edoxaban, and rivaroxaban are indicated for the
following: risk reduction of stroke and systemic embolism in
patients with NVAF (dabigatran, apixaban, edoxaban, and rivarox-
aban); treatment of deep vein thrombosis (DVT) and pulmonary
embolism (PE) (rivaroxaban and apixaban); treatment of DVT and
PE after parenteral anticoagulant therapy for 5 to 10 days (dabi-
gatran and edoxaban); risk reduction of recurrence of DVT and PE
(apixaban, dabigatran, and rivaroxaban); and prophylaxis of DVT,
which may lead to PE in patients undergoing hip replacement
surgery (dabigatran) or knee or hip surgery (apixaban and rivar-
oxaban) (Table 1).1-4 Warfarin is indicated for the prophylaxis and
treatment of DVT and PE; risk reduction of thromboembolic com-
plications associated with NVAF and/or cardiac valve replacement;
and to reduce the risk of death, recurrent myocardial infarction, and
thromboembolic events after myocardial infarction.27
Characteristics of DOACs
DOACs all have predictable, dose-dependent pharmacokinetics/
pharmacodynamics, and so, unlike warfarin, they do not require
routine monitoring of their anticoagulant activity.28 DOACs also
have a shorter half-life, resulting in a quicker “offset time” and
quicker time to maximum effect than warfarin (Table 2).
After oral administration, dabigatran etexilate is rapidly
metabolized to dabigatran, which reversibly inhibits both free and
clot-bound thrombin through interaction with its active site.1,29
Both peak plasma dabigatran levels and its peak effect on coagu-
lation parameters are achieved within 2 hours, and it has a half-life
of 12 to 17 hours.29 Dabigatran is excreted predominantly by the
kidneys, with more than 80% of systemically available dabigatraneliminated via urine.30 As a result, exposure to dabigatran in-
creases, and half-life is prolonged with worsening renal function,
with an approximately 3-fold increase in dabigatran exposure and a
1.5-fold increase in half-life with moderate impairment.1,31
Rivaroxaban selectively and competitively inhibits free and
prothrombinase/clot-associated factor Xa through reversible in-
teractions with its active site. It achieves peak plasma levels 3 to
4 hours after oral administration, with maximum prolongation of
coagulation tests reached 1 to 4 hours after administration.2,32 It
has a half-life of 6 to 9 hours and is partially excreted by the kidneys
(66%).2,32,33
Apixaban is an oral, reversible, direct active site inhibitor of free
and clot-bound factor Xa.3,34 It achieves peak plasma levels within
3 to 4 hours after oral administration and maximum increases in
clotting times at 3 hours.35 Apixaban has a half-life of 8 to 15 hours
and is partially excreted by the kidneys (25%-29%).34,35 For edox-
aban, plasma levels peak in 1 to 2 hours, with maximum activated
partial thromboplastin time (aPTT) occurring 1 to 3 hours after
administration.4,36 The drug is partially excreted by the kidneys
(35%) and has a half-life of 6 to 11 hours.4,36,37
Bleeding Risks
The following factors have been identiﬁed as increasing the risk
of bleeding in patients receiving oral anticoagulants: intensity of
anticoagulation, increasing age, genetic factors affecting VKA
metabolism and antithrombotic effect, prior stroke, history of
bleeding, anemia, comorbidity (hypertension, renal insufﬁciency,
and liver disease), and use of concomitant medication (eg, anti-
platelet drugs or nonsteroidal anti-inﬂammatory agents) or
alcohol.38
Bleeding Risks Associated With DOACs
As with all anticoagulant agents, treatment with DOACs is
associated with a risk of bleeding, either spontaneously or as a
result of trauma. Potential for uncontrolled bleeding may also force
delays in urgent surgery or invasive procedures until a patient is
satisfactorily coagulated.
In clinical trials, the incidence of major bleeding or nonmajor,
clinically relevant bleeding with DOACs was generally comparable
with or lower thanwarfarin (depending on dose), and the incidence
of ICH was lower than with warfarin.7-10 The variability observed
across clinical trials is likely caused by differences in patient char-
acteristics and indication as well as drug dosage and the duration of
treatment. Nonetheless, DOACs are associated with ~50% less
intracranial bleeding than VKAs.39
Studies using aggregated data have shown a decreased or
similar risk of major bleeding with DOACs versus VKAs depending
on the indication and drug dosage. However, it should be noted that
there are limitations with meta-analyses because of the heteroge-
neity of study populations, protocols, intervention, and follow-up
between trials, with some of these differences (especially
bleeding deﬁnitions) being difﬁcult to control for.
In a meta-analysis of 19 trials (all VTE or AF trials except 1 knee
surgery trial, N ¼ 40,364), DOAC use was associated with
Table 2
Pharmacodynamics of DOACs Compared With Warfarin
Characteristic Warfarin76,77 Dabigatran1,29,30 Rivaroxaban2,32,33 Apixaban3,34,35 Edoxaban4,36,37
Mechanism of
action
Inhibition of vitamin
K-dependent carboxylation
Direct thrombin
inhibitor (factor IIa)
Direct factor Xa inhibitor Direct factor Xa inhibitor Direct factor Xa inhibitor
Time to
maximum
effect
5-7 days < 2 hours 1-4 hours 3 hours 1-3 hours
Half-life 36-42 hours 12-17 hours 6-9 hours 8-15 hours 6-11 hours
Dosing QD BID QD BID QD
Elimination Hepatic metabolism Renal excretion Renal excretion/ hepatic
metabolism
Renal excretion/ hepatic
metabolism
Renal excretion/ hepatic
metabolism
Renal excretion 92% (metabolites) 80% (total); 77%
(unchanged drug)
66% (total); 36%
(unchanged drug)
25%-29% (total); 22%-24%
(unchanged drug)
35% (total); 24%
(unchanged drug)
BID ¼ twice daily; DOAC ¼ direct oral anticoagulant; QD ¼ every day.
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0.77; 95% conﬁdence interval [CI], 0.64-0.91; P ¼ .003).40 However,
pooled analysis of 42 trials (including all indications: VTE, AF, hip/
knee surgery, and medically ill patients) found no signiﬁcant dif-
ference between DOACs and active comparators (VKAs, lowe
molecular-weight heparin [LMWH], and/or aspirin) with respect to
major bleeding (odds ratio ¼ 0.93; 95% CI, 0.79-1.09). Similarly,
analysis of individual DOACs showed no signiﬁcant differences be-
tween DOACs and active comparators. A consistently lower risk of
bleeding was apparent for the acute treatment of VTE with DOACs
than with VKAs. However, in patients with NVAF, there were no
signiﬁcant differences in major bleeding between DOACs and VKA/
aspirin, and there was considerable heterogeneity among trials.40
In another meta-analysis of 10 VTE trials with apixaban, dabi-
gatran, edoxaban, or rivaroxaban (N ¼ 35,029), there were fewer
cases of major bleeding with DOACs for the acute treatment of VTE
compared with a parenteral anticoagulant followed by warfarin
(1.8 vs. 3.1 events per 100 patient years; relative risk¼ 0.62; 95% CI,
0.45-0.85). Also, no signiﬁcant differences in rates of major
bleeding were observed between the extended use of DOACs and
placebo (0.6 vs. 0.2 events per 100 patient years; relative risk
(RR) ¼ 1.93; 95% CI, 0.20-19.05; P ¼ .57).41
Observational studies of dabigatran or rivaroxaban have pro-
vided additional information on the potential for bleeding although
there are more published postmarketing data with dabigatran than
rivaroxaban because dabigatranwas the ﬁrst DOAC approved by the
US Food and Drug Administration (FDA). An ongoing pharmacovi-
gilance study of rivaroxaban in patients with NVAF (N ¼ 27,467)
using US Department of Defense electronic health care records
observed an incidence rate for major bleeds of 2.86 per 100 person
years and fatal bleeds of 0.08 per 100 person years over a 15-month
follow-up period.42 Gastrointestinal (GI) bleeds made up 88.7% of
major bleeding events in the study and ICH 50% of cases of fatal
bleeds. The 2-year analysis from this study, involving 39,052 pa-
tients with NVAF on rivaroxaban, yielded a similar incidence rate
for major bleeding (2.89 per 100 person years).43 GI bleeds were
again the most common major bleeding event (87.2%) followed by
ICH (8.1%).
The US Medicare study performed by the FDA is currently the
largest cohort (N ¼ 134,414) of dabigatran-treated patients to be
evaluated. This retrospective cohort study found that dabigatran
was associated with an incidence of major bleeding similar to that
of warfarin (42.7 vs. 43.9 per 1,000 person years, adjusted hazard
ratio [HR]¼ 0.97) in elderly patients ( 65 years of age) with NVAF.
In comparisonwith warfarin, dabigatranwas also associated with a
reduced risk of ICH (3.3 vs. 9.6 events per 1,000 patient years, HR ¼
0.34, P < .001) and an increased risk of major GI bleeding (34.2 vs.
26.5 events per 1,000 patient years, HR ¼ 1.28, P < .001), especially
in women aged  75 years and men aged  85 years.44A recently published observational study compared the risk of
major bleeding with dabigatran versus warfarin in a non-Medicare
NVAF population (n¼ 12,793 per group, mean age¼ 74 years). This
study, which used the US Department of Defense patient database,
found a reduced risk of ICH with dabigatran versus warfarin
(HR¼ 0.49; 95% CI, 0.30-0.79). However, the risks of major bleeding
(HR ¼ 0.87; 95% CI, 0.74-1.03) and major GI bleeding (HR ¼ 1.13;
95% CI, 0.94-1.37) with dabigatran were similar to warfarin, and
major lower GI bleeding events were more frequent (HR ¼ 1.30;
95% CI, 1.04-1.62) with dabigatran.45
Bleeding Management Treatment Algorithm for Patients on
DOACs
The primary emergency management of bleeding in the setting
of DOAC use essentially follows the same basic precepts used in any
hemorrhagic condition. However, there are a few nuances associ-
ated with DOAC pharmacology that should be understood in order
to limit the patient’s bleeding and extend the time until deﬁnitive
management can be obtained (ie, surgery, colonoscopy, and so on).
For air medical personnel, a working knowledge of some basic
methods used in assessing the degree of anticoagulation induced
by these therapies and the potential treatment options available
could be critical during transport of the hemorrhaging patient.
Figure 1 outlines a practical stepwise algorithm for EMS personnel
considering the management of a patient with acute bleeding who
is taking a DOAC.
Patient Stabilization
A continuing assessment of the patient’s vital signs should be
performed for guidance in hemodynamic stabilization. The
management of hypotension secondary to hemorrhage should
begin with ﬂuid resuscitation. If this resuscitation is prolonged,
caution should be used so as to not dilute the patient’s blood
volume and further exacerbate the inhibited coagulation condi-
tion. If needed, blood and blood products should be made avail-
able to treat any continued hemorrhaging. The source of the
bleeding should be identiﬁed if possible, and simple methods
such as mechanical compression should be initiated to limit the
blood loss. In cases in which there is evidence of ICH, caution
should be used to avoid over-resuscitating the patient, and blood
pressure should be closely monitored and controlled. Of course,
any further use of the anticoagulation therapy should be sus-
pended until a more thorough assessment is made by the
physician managing the patient.
Identifying Which DOAC
An identiﬁcation of the speciﬁc DOAC used, the patient’s pre-
scribed dosing, amount ingested, and the time that the last dosage
was taken can be important in the emergent management of these
Figure 1. Acute management of DOAC-related bleeding. DOAC ¼ direct oral antico-
agulant; FFP ¼ fresh frozen plasma; ICH ¼ intracranial hemorrhage; PCC ¼ pro-
thrombin complex concentrate; rFVIIa ¼ recombinant activated factor VII.
Table 3
Summary of Coagulation Tests Used in Clinical Practice
Anticoagulant Preferred Test
(Based on Availability)
Alternative Test
(Variable Results)
Warfarin78 INR PT
Dabigatran29,51,52,79 ECT or dTT aPTT/TT
Rivaroxaban46-48 Anti-factor Xa PT
Apixaban48,49 Anti-factor Xa dPT
Edoxaban36 Anti-factor Xa PT/aPTT
Enoxaparin50,80 Anti-factor Xa ACT
Heparin50,81 aPTT anti-Xa HA
ACT¼ activated clotting time; anti-Xa HA¼ anti-Xa heparin assay; aPTT¼ activated
partial thromboplastin time; dPT¼ dilute prothrombin time; dTT¼ dilute thrombin
time; ECT ¼ ecarin clotting time; INR ¼ international normalized ratio; PT ¼ pro-
thrombin time.
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available at the primary site, especially if the patient is incapaci-
tated and the family does not travel to the destination hospital.
Therefore, it is incumbent on EMS personnel to capture this infor-
mation if possible before leaving the scene of transport. The in-
dications for the different DOACs as well as their characteristics, as
listed in Tables 1 and 2, may help in determining which one is being
used in any particular case. It is also important for EMS personnel to
familiarize themselves with both the generic and trade names ofthese therapies because the patient and family members will not
always know the difference. A secure knowledge of which DOAC is
involved and the timing and extent of the dosing is critical in
guiding medical decisions regarding laboratory testing and treat-
ment countermeasures.Assessing Degree of Anticoagulation
Although none of the new oral anticoagulants require routine
laboratory monitoring, an ability to monitor these agents could be
useful in emergency situations such as acute bleeding or over-
doses. Table 3 outlines both preferred and alternative testing
methods for many of the anticoagulants that might be
encountered. Although certain tests for monitoring DOAC-
induced anticoagulation have been found to show a good linear
dose-dependent relationship, these are often unavailable at
smaller hospitals. There are some alternative tests that can pro-
vide qualitative evidence that the drug is effective in producing
some degree of anticoagulation, but the results are variable and
may not clearly indicate the extent of that effect. For the Xa in-
hibitors (rivaroxaban, apixaban, and edoxaban), the antifactor Xa
assays, which have been used for monitoring LMWHs in some
tertiary centers, may prove to be the best method to assess the
degree of anticoagulation although these assays need to be cali-
brated to the speciﬁc Xa inhibitor and results are also variable
depending on the reagent used.46-48 Prothrombin time assays may
be used as an alternative for assessing coagulation in patients
receiving rivaroxaban, and the dilute prothrombin time has been
used in the case of apixaban.47,49 However, the results are difﬁcult
to interpret beyond a qualitative perspective because of a lack of
standardization because of variability depending on the throm-
boplastin reagent used.48,50
Both the ecarin clotting time (ECT) and dilute thrombin time
(dTT) tests have shown to be fairly reliable assays to assess
coagulation in patients taking dabigatran.29,51 However, the
widespread availability of the dTT and ECT assays has been limited
and may be difﬁcult to interpret without prior experience. Stan-
dard aPTT and thrombin time testing, which are available in most
hospital laboratories, are sometimes used as an alternative to
provide a qualitative assessment of dabigatran levels. However,
these assays have a limited ability to quantify the amount of
dabigatran present.52Treatment Schemes
Early treatment responses to a patient who develops acute
bleeding while taking a DOAC should be graded according to the
evident severity of the hemorrhage (mild, moderate, or severe).
However, all management schemes begin with the usual EMS
principles of evaluation and resuscitation along with supportive
care.
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Because most of these agents have relatively short half-lives
compared with warfarin, mild bleeding cases can usually be
managed by simply stopping the drug for a few doses. In fact, the
majority of bleeding cases will fall into this category and do not
require any active reversal or supplementation of factors. In pa-
tients with adequate hepatic and renal function, DOACs will be
largely cleared from the body within about 12 hours after the most
recent dose. Occasionally, the residual effect of their pharmacology
on the coagulation cascade may persist for a while longer. There-
fore, continued monitoring of these patients is imperative in the
event that the bleeding progresses and treatment responses need
to be escalated.
Moderate Bleeding
Moderate bleeding corresponding to a drop in systolic blood
pressure or other signiﬁcant changes in vital signs will require ﬂuid
resuscitation and possible transfusion with blood or blood prod-
ucts. If there is evidence of anticoagulation by testing or history,
fresh frozen plasma can be used as a ﬁrst-line replacement of fac-
tors. Oral administration of activated charcoal might help in pre-
venting systemic absorption if it is initiated soon after ingestion
(< 2 hours) of the last dose of DOAC.53 Hemodialysis can be
considered for removal of the direct thrombin inhibitor dabigatran
although clinical data are limited and it is usually reserved for large
overdoses and life-threatening bleeding events such as ICH.53-55
However, dialysis is not effective for removing the factor Xa in-
hibitors, which are highly protein bound. If there is an obvious
source of bleeding that might require surgical intervention or a
gastrointestinal procedure, the appropriate specialists should be
alerted early in the management process. As new speciﬁc reversal
agents become available with FDA approval, they might also be
considered as a part of the management scheme.
Severe Life-threatening Bleeding
Obviously, if the bleeding is severe, then all the prior treatment
processes will apply as the patient is being stabilized. Currently,
commercially available plasma products containing high concen-
trations of factors II, VII, IX, and X (called 3- or 4-factor PCC) or
activated PCC can be given to overcome the inhibitory effect of the
drugs. Recombinant activated factor VII can also be considered.
These drugs are often expensive and not always available at many
community hospitals. There is also limited clinical trial experience
regarding the dosing and effectiveness of these agents as it applies
to treating bleeding secondary to DOAC usage.53
In October 2015, the FDA approved idarucizumab (a speciﬁc
reversal agent for dabigatran) for use in emergency surgery/urgent
procedures or in life-threatening or uncontrolled bleeding. Reversal
agents for factor Xa inhibitors (andexanet alfa and ciraparantag) are
in development and potentially will be available in the near future.
Future Directions and Speciﬁc Reversal Agents
We are likely to see greater DOAC usage as their indications and
availability expand. As with any anticoagulant, there is an inherent
bleeding risk with these agents, especially if there is an associated
traumatic event or medical condition (such as aneurysm or peptic
ulcer) that could increase the likelihood of bleeding. Naturally,
medical personnel would like to have a speciﬁc reversal agent in
cases of overdose or acute hemorrhage or when emergency surgery
is required.
We are accustomed to using vitamin K for those cases involving
warfarin. However, the emergency management of bleeding in
patients taking warfarin is more complex than generally assumed,
and there are some misconceptions regarding its reversibility.
Because of its slow onset of action, vitamin K is not reallyconsidered an emergency “antidote” or “reversal agent” for
warfarin.56 Additionally, the effects of warfarin are known to last
for days, which makes it difﬁcult to plan a management strategy
based on the last known dosing. The 4-factor PCC (Kcentra, CSL
Behring, King of Prussia, PA) is indicated, in combination with
vitamin K, for the urgent reversal of acquired coagulation factor
deﬁciency induced by VKA (eg, warfarin) therapy in adult patients
with acute major bleeding or in the case of a need for an urgent
surgery or invasive procedure.21 Vitamin K therapy is not effective
in bleeding secondary to DOAC anticoagulation.Idarucizumab
Idarucizumab (BI 655075; Boehringer Ingelheim, Ridgeﬁeld, CT)
is a humanized mouse monoclonal antibody fragment targeted
against dabigatran. Idarucizumab mimics thrombin’s molecular
recognition and binding of dabigatran, exhibiting an afﬁnity for
dabigatran approximately 350 times greater than dabigatran’s af-
ﬁnity for thrombin.57 In phase I clinical trials, idarucizumab has
shown immediate, complete, and sustained reversal of the antico-
agulant effects of dabigatran in healthy volunteers with normal
renal function, volunteers aged 65 to 80 years, and volunteers aged
45 to 80 years with mild or moderate renal impairment. In the
absence of dabigatran, idarucizumab has shown no effect on
coagulation parameters or thrombin formation, suggesting that
idarucizumab in itself has no procoagulant effect and has beenwell
tolerated at all doses in these phase I trials.58-60 The overall fre-
quency of AEs within healthy volunteers in phase I trials was 25%
for both idarucizumab and placebo recipients (55/224 vs. 26/105).61
Among those receiving idarucizumab, headache was the only AE
reported in  5% of participants (n ¼ 12, 5%).
Dabigatran reversal by idarucizumab is being evaluated in a
prospective cohort phase III trial (RE-VERSE AD [NCT02104947])
involving patients who have serious bleeding or required an urgent
procedure.62 Published results of an interim analysis (N ¼ 90)
showed that idarucizumab normalized coagulation test results (dTT
and ECT) in 88% to 98% of patients who had elevated clotting times
at baseline, with this effect being evident within minutes. Among
the patients with serious bleeding, hemostasis as assessed by the
investigators was restored at a median of 11.4 hours although this
parameter could not be assessed in a number of patients, such as
those with ICH or retroperitoneal bleeding. Normal intraoperative
hemostasis was also reported in 92% of patients who underwent
urgent procedures, and only 1 patient (inwhom anticoagulants had
not been reinitiated) experienced a thrombotic event within
72 hours after idarucizumab. Plasma concentrations of unbound
dabigatran were reduced to levels near or at the lower limit of
quantiﬁcation in all but 1 patient by the end of the idarucizumab
infusion and remained at this level for 24 hours in 78% of patients.
Rebound increases in unbound dabigatran levels observed at
12 and 24 hours in the remaining patients (6 and 16, respectively)
may be caused by redistribution of extravascular dabigatran into
the intravascular compartment. A second 5-g dose of idarucizumab
may be considered in patients with both clinically relevant bleeding
and elevated coagulation parameters or in those patients who
require a second emergency surgery/urgent procedure and have
elevated coagulation parameters. However, the safety and effec-
tiveness of a second dose has not yet been established.61
AEs reported in  5% of patients in this interim analysis were
hypokalemia (n¼ 9), delirium (n ¼ 9), constipation (n ¼ 8), pyrexia
(n ¼ 7), and pneumonia (n ¼ 7). Each of the 26 deaths (11 of which
occurred within the ﬁrst day of idarucizumab dosing) were
attributed to a complication of the index event or comorbidities.
Thrombotic events were reported in 5 patients: one 2 days and
4  7 days after idarucizumab administration. None of these events
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was attributed to the patient’s underlying medical condition.61
As with all proteins, there is potential for immunogenicity with
idarucizumab, and thus plasma samples from 283 healthy volun-
teers (idarucizumab recipients, n ¼ 224) in the phase I trials have
been tested for antibodies cross-reacting with idarucizumab using
an electrochemiluminescence-based assay. Pre-existing antibodies
with cross-reactivity to idarucizumab were detected in 13% of in-
dividuals, most of which had low titers, and no impact on the
pharmacokinetics or reversal effects of idarucizumabwere noted in
these individuals. Most (97%) of these pre-existing antibodies had
speciﬁcity for the C-terminus, a region that does not bind with
dabigatran. Treatment-emergent anti-idarucizumab antibodies
with low titers were observed in 4% of idarucizumab recipients;
56% of these had speciﬁcity for the C-terminus, 22% had speciﬁcity
for the variable region, and 11% each had mixed or indeterminate
speciﬁcity.
Idarucizumab is currently the only FDA-approved speciﬁc
reversal agent for a DOAC. It is supplied as 2 single-use vials each
containing 2.5 g/50 mL idarucizumab. These vials should be stored
in a refrigerator but can be kept at room temperature for up to
48 hours before use if unopened and stored in the original pack-
aging to protect from light or up to 6 hours when exposed to light.
Idarucizumabmay be administered as 2 consecutive infusions or by
bolus injection by injecting both vials consecutively.61
Andexanet Alfa
Andexanet alfa (andexanet; r-Antidote, PRT064445; Portola
Pharmaceuticals, South San Francisco, CA) is a modiﬁed, recombi-
nant human factor Xa that binds to direct factor Xa inhibitors such
as apixaban, edoxaban, and rivaroxaban and indirect factor Xa in-
hibitors, such as LMWHs. Structural modiﬁcations in the protein
fromnative factor Xa have resulted in andexanet having no intrinsic
procoagulant or anticoagulant activity. It binds to factor Xa in-
hibitors with a similar afﬁnity to that of native factor Xa, and also
has the potential to reverse the anticoagulant effects of indirect
factor Xa inhibitors (such as fondaparinux) by competing with
factor Xa for antithrombin binding.63
Multiple double-blind, placebo-controlled phase II trials
involving healthy volunteers have been conducted to investigate
the role of andexanet as a speciﬁc reversal agent to various factor
Xa inhibitors. In the ﬁrst of these trials, a single IV bolus dose of
andexanet 90 mg administered after 6 days of treatment with
apixaban 5 mg twice daily reduced antifactor Xa activity by 65%
within 2 minutes of andexanet administration, and this was
accompanied by decreases in plasma concentrations of unbound
apixaban.64 Five of 9 participants in this trial experienced 1 or more
mild AEs. In a similar trial, andexanet administered at IV bolus
doses of 210, 420, 600, and 720 mg reduced antifactor Xa activity
after 6 days of treatment with rivaroxaban 20 mg daily by 20%, 53%,
70%, and 81%, respectively, and unbound plasma rivaroxaban con-
centrations by 32%, 51%, 75%, and 70%, respectively. AEs reported in
andexanet and placebo recipients (N ¼ 18) included mild infusion-
related reactions (n ¼ 3) and postprocedural hematoma, headache,
or postural dizziness (n ¼ 2 each).65,66 In another trial, andexanet
administered as a 420-mg IV bolus dose and a continuous infusion
for 45 minutes or 2 hours at 4 mg/min provided > 90% reversal of
apixaban-mediated antifactor Xa activity, which was sustained
throughout both infusion periods. Plasma concentrations of un-
bound apixaban also decreased immediately after the bolus injec-
tion, and, thereafter, concentrations paralleled the level of
antifactor Xa activity. Complete and sustained reversal of inhibition
of thrombin generation was achieved with the 2-hour infusion,
with levels remaining within the normal range 2 hours after
completion of the infusion. Andexanet was well tolerated with noserious or severe AEs.67 Similar results were also achieved by an
andexanet 600-mg bolus and an 800-mg bolus followed by
8 mg/min infusion for 1 hour after anticoagulation with edoxaban
60 mg daily for 6 days. Antifactor Xa activity decreased by 52% and
73%, respectively, immediately after the bolus doses, remained
constant during the infusion, and then returned to placebo levels
within 2 hours after the infusion. Andexanet was well tolerated
with no thrombotic events or serious or severe AEs.68
Results from 2 separate phase III trials have been published;
these investigated the reversal effects of andexanet in healthy
volunteers aged 50 to 75 years who had received rivaroxaban 20mg
once daily for 4 days (ANNEXA-R, NCT02220725) or apixaban 5 mg
twice daily for 3.5 days (ANNEXA-A, NCT0227725).69 Part 1 of
these trials evaluated a bolus IV dose (ANNEXA-R: 800 mg and
ANNEXA-A: 400 mg), and part 2 evaluated these respective bolus
doses followed by a 120-minute infusion (ANNEXA-R: 8 mg/min
and ANNEXA-A: 4 mg/min). In both of these trials, andexanet
reversed the anticoagulant activity of apixaban or rivaroxaban as
measured by antifactor Xa activity and thrombin generationwithin
minutes, and these effects were sustained for the duration of the
infusion. These biomarkers returned to placebo levels 1 to 3 hours
after the cessation of andexanet. No serious AEs or thrombotic
events were reported. A third ongoing study (ANNEXA-4,
NCT02329327) is investigating the effects of andexanet in patients
 18 years of age who are experiencing a major bleeding episode
while receiving an oral factor Xa inhibitor or enoxaparin.70
Ciraparantag
Ciraparantag (previously, aripazine; PER977; Perosphere Inc
Danbury, CT) is a synthetic, small water-soluble molecule that has
been developed as a reversal agent for unfractionated heparin,
LMWH, factor Xa inhibitors, and dabigatran.71,72 Ciraparantag binds
with large molecules, such as heparins, and with smaller molecules
such as DOACs, thus inhibiting subsequent interactions between
these anticoagulants and antithrombin or activated clotting factors.
Ciraparantag does not bind to any of the human coagulation factors
or serum albumin and thus has no procoagulant effect.71 Cirapar-
antag reversed anticoagulation induced by DOACs (edoxaban,
rivaroxaban, apixaban, and dabigatran) in rats as measured by
thromboelastography, prothrombin time, and/or aPTT as well as
bleeding volume in the rat tail transection model.73 This reversal
agent has also shown complete reversal of rivaroxaban and apix-
aban antifactor Xa activity ex vitro in platelet-poor plasma from
healthy volunteers.72
In a phase I/II trial, ciraparantag reversed anticoagulant activity
of the LMWH enoxaparin as assessed by whole blood clotting time
(WBCT) within 20 minutes of a 100-mg IV dose and within 5 mi-
nutes of a 200-mg IV dose. No rebound anticoagulation or signs of
procoagulant effects (measured by D-dimer, prothrombin fragment
1.2, and tissue factor pathway inhibitor) were observed, and AEs
were limited to transient temperature sensations and ﬂushing.74
Ciraparantag (single IV doses of 100-300 mg) also reversed the
anticoagulant effects of edoxaban (single 60-mg dose) as measured
by WBCT in healthy volunteers within a separate double-blind,
dose escalation trial. Reductions in WBCT to within 10% above
baseline levels were achieved within 10 minutes, and WBCT
remained at or below this level for 24 hours. There were no signs of
procoagulant activity, and AEs included transient perioral and facial
ﬂushing and dysgeusia and moderate headache (in 1 individual).75
Phase II trials (NCT02206087 and NCT02207257) with ciraparantag
are ongoing.
Conclusions
Overall, DOACs have been shown to incur less bleeding risk than
warfarin. However, further studies are still needed to completely
R.L. Summers, S.A. Sterling / Air Medical Journal 35 (2016) 148e155154deﬁne procedures for themanagement of acute bleeding associated
with DOACs as compared with that for other traditional anticoag-
ulants. The future potential for agents that can be used for the rapid
reversal of their anticoagulation effects will certainly be an
important part of those procedures.
The long-term use of oral anticoagulants for the prophylaxis and
treatment of thromboembolic disease is widespread and
increasing, with VKAs no longer being the only therapeutic option.
The DOACs have been shown to provide comparable antith-
rombotic efﬁcacy as warfarin in phase III trials as well as a number
of clinical advantages such as ﬁxed dosing without the need for
routine laboratory monitoring. They were also associated with
comparable or lower incidence of major bleeding or nonmajor
clinically relevant bleeding and lower rates of ICH than warfarin in
these trials. However, as with all anticoagulants, DOACs are asso-
ciated with a risk of spontaneous bleeding or bleeding as a result of
trauma, and the risk of uncontrolled bleedingmay also delay urgent
surgery or invasive procedures until coagulation is restored.
Because air medical personnel are increasingly likely to
encounter patients receiving DOACs, it is important that they have
an understanding of these agents and how to manage patients
receiving different DOACs who have emergent bleeding. This article
provides a practical stepwise algorithm that should help EMS
professionals to manage patients with acute bleeding who are
receiving a DOAC. Idarucizumab has recently been approved for use
in dabigatran-treated patients who require anticoagulant reversal
for emergency surgery or urgent procedures or for life-threatening
or uncontrolled bleeding. There are also a number of other DOAC
reversal agents in development. The availability of these agents is
expected to improve the emergency management of patients
receiving DOACs.
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